What assumption about biosimilars entering the market is often incorrect when designing benefit programs?
Answered at 21:30 in AH118 - Chemo, Cars, & Where Health Plan Savings May be Hiding, with Brian Cotter · The Astonishing Healthcare Podcast
What assumption about biosimilars entering the market is often incorrect when designing benefit programs?
A common assumption is that biosimilars are always lower cost than the reference drug. However, while biosimilars have dropped reference drug costs and benefited patients, at the current time the reference drug may actually be significantly lower cost than the biosimilar. Plan sponsors must analyze current pricing to determine the actual lowest-cost option rather than relying on this assumption.
Full answer and detailsRead the whole answer, key facts and every other question from this episode
In short
A common assumption is that biosimilars are always lower cost than the reference drug.
Brian Cotter, Founder at Bright Spot Insights · AH118 - Chemo, Cars, & Where Health Plan Savings May be Hiding, with Brian Cotter · The Astonishing Healthcare Podcast · answer at 21:30
Key takeaways
- A common assumption is that biosimilars are always lower cost than the reference drug.
Quote to remember
“Assume the data is incorrect until proven otherwise. You need to work through the steps to validate the data before you can start digging in and understanding what price variation you see.”
— Brian Cotter
The full answer · about 2 min
A common assumption is that biosimilars are always lower cost than the reference drug. However, while biosimilars have dropped reference drug costs and benefited patients, at the current time the reference drug may actually be significantly lower cost than the biosimilar. Plan sponsors must analyze current pricing to determine the actual lowest-cost option rather than relying on this assumption.
Key facts
- Oxaliplatin ASP price dropped from $2,053 in 2012 to $9.40 in Q1 2026—a 99% reduction
- One hospital listed oxaliplatin at $29,595 compared to Medicare reimbursement under $10
- Specialty drug spend now represents 55-60% of pharmacy spend
- Pharmacy spend represents 25-30% of total plan spend
- 431 drugs had price drops between Q1 2025 and Q1 2026, with drops up to 99%
People, companies and topics mentioned
More answers from this episode
- 2:34What is specialty pharmacy drug spending as a percentage of total plan spend, and how has it grown?
- 5:29What was the price drop for oxaliplatin (Eloxatin) between 2012 and Q1 2026 after converting from brand to generic?
- 9:00How many Medicare J codes for specialty drugs on the medical benefit showed price drops in Q1 2025 to Q1 2026?
- 12:00How much can plan sponsors save by redirecting chemotherapy patients to lower-cost, high-quality providers with direct contracts?
- 15:45Why is data validation critical when using price transparency files and claims data to identify drug pricing opportunities?